PD-1 regulates CD4 T cell differentiation and trafficking in response to hyperlipidemia in mice and humans 2260972

Abstract Introduction Programmed cell death protein 1 (PD-1) is a well-studied regulator of T cell activation. It is also highly expressed on T follicular helper cells, and global deletion of PD-1 or its ligands, PD-L1 and PD-L2, has been shown to diminish antigen-specific B cell responses and formation of memory B cells. Given that PD-1 blockade immunotherapy has recently been associated with accelerated progression of atherosclerosis, we have developed a murine model with CD4-specific inducible loss of PD-1 to further investigate how PD-1 regulates the CD4 T cell, and consequently, the B cell response, both at baseline and in response to hyperlipidemia. We have also probed two cohorts of patients with coronary artery disease (CAD) to investigate the prevalence and phenotype of PD-1-expressing CD4 T cells among PBMCs. Methods To study loss-of-function in mice, we have generated CD4CreERT2Pdcd1fl/fl mice, with tamoxifen-inducible CD4-specific knockout of PD-1. In our human studies, we assembled a matched cohort of patients with low and high severity CAD, determined by coronary angiography, and performed CITE-Seq on PBMCs collected at the time of imaging. Results During hyperlipidemia, CD4-specific loss of PD-1 results in increased CD4 T cell activation and differentiation into Th subtypes, with corresponding decreases in the frequency of naïve CD4 T cells. We also observe increases in CXCR3 and CCR5 in CD4 T cells, both associated with trafficking to atherosclerotic lesions. In CAD patients, PD-1+ CD4s express these same markers. In the B cells, we observe major changes to B cell surface markers without PD-1 signaling, suggesting disruptions in T-dependent B cell activation. Conclusion Altogether, these data suggest that PD-1 is not only an important regulator of T cell activation, but also a regulator of T cell trafficking during atherosclerosis. Furthermore, the PD-1 signaling axis between CD4s and B cells may maintain B cell homeostasis. Funding Source Leducq Foundation, NIH T32AI007496-29, NIH R01 AI17211 Topic Categories Immune Response Regulation: Cellular Mechanisms (IRC)

Authors

Institutions

Publication Details

Journal
The Journal of Immunology
Published
2026-07-28
DOI
https://doi.org/10.1093/jimmun/vkag141.1011
Primary Topic
Atherosclerosis and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PD-1 regulates CD4 T cell differentiation and trafficking in response to hyperlipidemia in mice and humans 2260972

Katherine Root, Hema Kothari, Coleen McNamara, Chantel McSkimming et al.
The Journal of Immunology
Atherosclerosis and Cardiovascular Diseases
article

PD-1 regulates CD4 T cell differentiation and trafficking in response to hyperlipidemia in mice and humans 2260972

Katherine Root, Hema Kothari, Coleen McNamara, Chantel McSkimming, Melissa Marshall, Sydney Blimbaum, Corey Williams
article en

Abstract

Abstract Introduction Programmed cell death protein 1 (PD-1) is a well-studied regulator of T cell activation. It is also highly expressed on T follicular helper cells, and global deletion of PD-1 or its ligands, PD-L1 and PD-L2, has been shown to diminish antigen-specific B cell responses and formation of memory B cells. Given that PD-1 blockade immunotherapy has recently been associated with accelerated progression of atherosclerosis, we have developed a murine model with CD4-specific inducible loss of PD-1 to further investigate how PD-1 regulates the CD4 T cell, and consequently, the B cell response, both at baseline and in response to hyperlipidemia. We have also probed two cohorts of patients with coronary artery disease (CAD) to investigate the prevalence and phenotype of PD-1-expressing CD4 T cells among PBMCs. Methods To study loss-of-function in mice, we have generated CD4CreERT2Pdcd1fl/fl mice, with tamoxifen-inducible CD4-specific knockout of PD-1. In our human studies, we assembled a matched cohort of patients with low and high severity CAD, determined by coronary angiography, and performed CITE-Seq on PBMCs collected at the time of imaging. Results During hyperlipidemia, CD4-specific loss of PD-1 results in increased CD4 T cell activation and differentiation into Th subtypes, with corresponding decreases in the frequency of naïve CD4 T cells. We also observe increases in CXCR3 and CCR5 in CD4 T cells, both associated with trafficking to atherosclerotic lesions. In CAD patients, PD-1+ CD4s express these same markers. In the B cells, we observe major changes to B cell surface markers without PD-1 signaling, suggesting disruptions in T-dependent B cell activation. Conclusion Altogether, these data suggest that PD-1 is not only an important regulator of T cell activation, but also a regulator of T cell trafficking during atherosclerosis. Furthermore, the PD-1 signaling axis between CD4s and B cells may maintain B cell homeostasis. Funding Source Leducq Foundation, NIH T32AI007496-29, NIH R01 AI17211 Topic Categories Immune Response Regulation: Cellular Mechanisms (IRC)

The Journal of ImmunologyVol. 215(Supplement_1)
University of Virginia (US)
Good health and well-being
Openalex Percentile: Top 16%
Atherosclerosis and Cardiovascular Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.